FDA finalizes guidance for efficient biosimilars meetings, per BsUFA III
Regulatory NewsEmily Hayes
Biologics/ biosimilars/ vaccinesBsUFAGuidanceHealth Authority meeting and communication strategyUnited StatesRegulatory NewsEmily HayesBiologics/ biosimilars/ vaccinesBsUFAGuidanceHealth Authority meeting and communication strategyUnited States